Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rallybio Corporation (RLYB)
USD16.17
+0.16 (+1.00%)
US NASDAQ Healthcare Biotechnology
Address
234 Church Street 6510
New Haven, CT, US
New Haven, CT, US
CEO
Stephen Uden
Website
rallybio.com
IPO
2021-07-29
CIK 1739410 ISIN US75120L2097
Description
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD16.17
+0.16 (+1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
253.1K
Beta
-0.88
Float Shares
3.15M
Free Float %
59.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.21% | -3.90% | +69.04% | +191.08% | +167.24% | +155.56% | +489.50% | -67.76% | -87.56% | -87.56% | -87.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
16.17
DCF (Unlevered)
11.30
-30.1%
DCF (Levered)
6.96
-56.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.89
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+34.9% ★ Q1'26: +0.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+85.1% ★ Q1'26: +13.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,748.7% Q1'26: -3,763.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3,270.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-826.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.4% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
636.0K
est: 673.8K (-5.6%)
|
858.0K
est: 700.0K (+22.6%)
|
80.0K
80.0K – 80.0K
-88.6% YoY
|
87.90M
87.90M – 87.90M
+109,775.0% YoY
|
87.50M
87.50M – 87.50M
-0.5% YoY
|
89.00M
89.00M – 89.00M
+1.7% YoY
|
| EBITDA |
-60.37M
est: 134.7K (-44,898.1%)
|
-27.97M
est: 140.0K (-20,080.1%)
|
16.0K
16.0K – 16.0K
-88.6% YoY
|
17.58M
17.58M – 17.58M
+109,781.9% YoY
|
17.50M
17.50M – 17.50M
-0.5% YoY
|
17.80M
17.80M – 17.80M
+1.7% YoY
|
| EBIT |
-60.50M
est: 134.7K (-44,995.3%)
|
-28.06M
est: 140.0K (-20,145.9%)
|
16.0K
16.0K – 16.0K
-88.6% YoY
|
17.58M
17.58M – 17.58M
+109,781.9% YoY
|
17.50M
17.50M – 17.50M
-0.5% YoY
|
17.80M
17.80M – 17.80M
+1.7% YoY
|
| Net Income |
-57.78M
est: -63.95M (+9.7%)
|
-8.98M
est: -10.13M (+11.4%)
|
-31.07M
-31.07M – -31.07M
-206.7% YoY
|
-64.85M
-64.85M – -64.85M
-108.7% YoY
|
-17.56M
-17.56M – -17.56M
+72.9% YoY
|
22.07M
22.07M – 22.07M
+225.6% YoY
|
| SGA |
19.63M
est: 6.81M (+188.1%)
|
14.33M
est: 7.08M (+102.4%)
|
808.8K
808.8K – 808.8K
-88.6% YoY
|
888.72M
888.72M – 888.72M
+109,775.1% YoY
|
884.67M
884.67M – 884.67M
-0.5% YoY
|
899.84M
899.84M – 899.84M
+1.7% YoY
|
| EPS |
-10.64
est: -11.36 (+6.3%)
|
-1.59
est: -1.80 (+11.7%)
|
-5.52
-5.52 – -5.52
-206.7% YoY
|
-11.52
-11.52 – -11.52
-108.7% YoY
|
-3.12
-3.12 – -3.12
+72.9% YoY
|
3.92
3.92 – 3.92
+225.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-29.97M
OE per share TTM
-5.39
Owner's Yield
-40.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
198.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
45
Total invested
20.73M
Insider transactions (90d)
2
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David C. Ott | 4.19M | 13.10% | — | 4.19M | — | — | IN | United States | 2021-08-09 | ↗ |
| 2 | O. Andreas Halvorsen | 4.19M | 13.10% | — | 4.19M | — | — | IN | Norway | 2021-08-09 | ↗ |
| 3 | Rose S. Shabet | 4.19M | 13.10% | — | 4.19M | — | — | IN | United States | 2021-08-09 | ↗ |
| 4 | Viking Global Investors LP | 4.19M | 13.10% | — | 4.19M | — | — | PN | Delaware | 2021-08-09 | ↗ |
| 5 | Viking Global Opportunities GP LLC | 4.19M | 13.10% | — | 4.19M | — | — | OO | Delaware | 2021-08-09 | ↗ |
| 6 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.19M | 13.10% | — | 4.19M | — | — | PN | Cayman Islands | 2021-08-09 | ↗ |
| 7 | Viking Global Opportunities Portfolio GP LLC | 4.19M | 13.10% | — | 4.19M | — | — | OO | Delaware | 2021-08-09 | ↗ |
| 8 | David Bonderman | 3.03M | 9.70% | — | 3.03M | — | — | IN | United States of America | 2021-08-12 | ↗ |
| 9 | James G. Coulter | 3.03M | 9.70% | — | 3.03M | — | — | IN | United States of America | 2021-08-12 | ↗ |
| 10 | TPG Group Holdings (SBS) Advisors, Inc. | 3.03M | 9.70% | — | 3.03M | — | — | CO | Delaware | 2021-08-12 | ↗ |
| 11 | Canaan Partners XI LLC | 2.41M | 7.50% | 2.41M | — | 2.41M | — | OO | — | 2022-02-08 | ↗ |
| 12 | Canaan XI L.P. | 2.41M | 7.50% | 2.41M | — | 2.41M | — | PN | — | 2022-02-08 | ↗ |
| 13 | Daniel R. Omstead | 2.31M | 7.20% | — | 2.31M | 2.31M | — | HC, IN | Delaware | 2022-01-21 | ↗ |
| 14 | Tekla Capital Management LLC | 2.31M | 7.20% | — | 2.31M | 2.31M | — | IA, CO | Delaware | 2022-01-21 | ↗ |
| 15 | Ronald Hunt | 2.30M | 7.20% | 1.0K | 2.30M | 1.0K | 2.30M | IN | — | 2022-02-11 | ↗ |
| 16 | Vijay Lathi | 2.30M | 7.20% | — | 2.30M | — | 2.30M | IN | — | 2022-02-11 | ↗ |
| 17 | Novo Holdings A/S | 2.30M | 6.20% | 2.30M | — | 2.30M | — | CO | Denmark | 2022-11-17 | ↗ |
| 18 | NF Investment Holdings Limited | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 19 | Nan Fung Group Holdings Limited | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 20 | Nan Fung Life Sciences Holdings Limited | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 21 | Pivotal Life Sciences Holdings Limited | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 22 | Pivotal Partners Ltd | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 23 | Pivotal bioVenture Partners Fund I G.P., L.P. | 2.27M | 7.30% | — | 2.27M | — | 2.27M | PN | — | 2021-08-12 | ↗ |
| 24 | Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 2.27M | 7.30% | — | 2.27M | — | 2.27M | CO | — | 2021-08-12 | ↗ |
| 25 | Pivotal bioVenture Partners Fund I, L.P. | 2.27M | 7.30% | — | 2.27M | — | 2.27M | PN | — | 2021-08-12 | ↗ |
| 26 | New Leaf Venture Associates III, L.P. | 2.15M | 6.70% | — | 2.15M | — | 2.15M | PN | — | 2022-02-11 | ↗ |
| 27 | New Leaf Venture Management III, L.L.C. | 2.15M | 6.70% | — | 2.15M | — | 2.15M | OO | — | 2022-02-11 | ↗ |
| 28 | New Leaf Ventures III, L.P. | 2.15M | 6.70% | — | 2.15M | — | 2.15M | PN | — | 2022-02-11 | ↗ |
| 29 | New Leaf BPO Associates II, L.P. | 153.8K | 0.50% | — | 153.8K | — | 153.8K | PN | — | 2022-02-11 | ↗ |
| 30 | New Leaf BPO Management II, L.L.C. | 153.8K | 0.50% | — | 153.8K | — | 153.8K | OO | — | 2022-02-11 | ↗ |
| 31 | New Leaf Biopharma Opportunities II, L.P. | 153.8K | 0.50% | — | 153.8K | — | 153.8K | PN | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
45
+0 vs prev Q
New positions
4
Closed positions
4
Increased
11
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AJU IB INVESTMENT CO., LTD. | 754.7K +— (+0.0%) | 4.14M +3.8M (+997.8%) | 0.21% -1.474 pp | 18.18% +17.850 pp | USD0.96 -28.1% | 5 qtrs — |
| 2 | VIKING GLOBAL INVESTORS LP | 4.19M +— (+0.0%) | 2.88M +784.8K (+37.5%) | 9.31% -0.045 pp | 0.01% +0.002 pp | USD17.58 -68.8% | 18 qtrs — |
| 3 | JOHNSON & JOHNSON | 3.64M +— (+0.0%) | 2.49M +680.4K (+37.5%) | 8.07% -0.039 pp | 0.45% +0.091 pp | USD1.36 +303.7% | 7 qtrs — |
| 4 | 5AM VENTURE MANAGEMENT, LLC | 3.63M +— (+0.0%) | 2.49M +679.3K (+37.5%) | 8.06% -0.039 pp | 0.78% +0.120 pp | USD2.49 +120.5% | 18 qtrs — |
| 5 | TPG GP A, LLC | 3.03M +— (+0.0%) | 2.09M +575.4K (+38.0%) | 6.72% -0.033 pp | 0.08% -0.005 pp | USD9.54 -42.5% | 17 qtrs — |
| 6 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 2.40M +— (+0.0%) | 1.65M +449.7K (+37.5%) | 5.34% -0.026 pp | 0.64% -0.056 pp | USD16.97 -67.6% | 18 qtrs — |
| 7 | FMR LLC | 1.69M +— (+0.0%) | 1.16M +317.0K (+37.5%) | 3.76% -0.018 pp | 0.00% +0.000 pp | USD15.27 -64.0% | 18 qtrs — |
| 8 | ALMITAS CAPITAL LLC | 1.53M -9.1K (-0.6%) | 1.05M +281.7K (+36.7%) | 3.39% -0.037 pp | 0.23% +0.055 pp | USD0.41 +1,239.0% | 7 qtrs — |
| 9 | VANGUARD GROUP INC | 1.02M +16.6K (+1.7%) | 697.1K +198.3K (+39.8%) | 2.26% +0.026 pp | 0.00% +0.000 pp | USD8.56 -35.9% | 18 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 835.7K +120.9K (+16.9%) | 573.4K +216.7K (+60.7%) | 1.85% +0.261 pp | 0.00% +0.000 pp | USD1.11 +394.6% | 8 qtrs — |
| 11 | CANAAN PARTNERS XI LLC | 450.0K +— (+0.0%) | 308.7K +84.2K (+37.5%) | 1.00% -0.005 pp | 0.23% +0.007 pp | USD9.54 -42.5% | 17 qtrs — |
| 12 | MARINER, LLC | 404.5K +— (+0.0%) | 277.6K +75.7K (+37.5%) | 0.90% -0.004 pp | 0.00% +0.000 pp | USD5.91 -7.1% | 14 qtrs — |
| 13 | CITADEL ADVISORS LLC | 253.8K -184.9K (-42.1%) | 174.2K -44.8K (-20.4%) | 0.56% -0.415 pp | 0.00% +0.000 pp | USD0.51 +976.5% | 4 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 248.0K +3.0K (+1.2%) | 170.2K +47.9K (+39.2%) | 0.55% +0.004 pp | 0.00% +0.000 pp | USD7.81 -29.7% | 18 qtrs — |
| 15 | BLACKROCK, INC. | 141.7K +— (+0.0%) | 97.2K +26.5K (+37.5%) | 0.31% -0.002 pp | 0.00% +0.000 pp | USD1.15 +377.4% | 6 qtrs — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 100.7K -35.6K (-26.1%) | 69.1K +1.1K (+1.6%) | 0.22% -0.080 pp | 0.00% +0.000 pp | USD0.47 +1,068.1% | 3 qtrs — |
| 17 | XTX TOPCO LTD | 97.3K +38.2K (+64.6%) | 66.8K +37.3K (+126.4%) | 0.22% +0.084 pp | 0.00% +0.000 pp | USD0.35 +1,468.6% | 8 qtrs — |
| 18 | ACADIAN ASSET MANAGEMENT LLC | 83.5K -6.8K (-7.5%) | 56.0K +12.0K (+27.3%) | 0.19% -0.016 pp | 0.00% +0.000 pp | USD1.46 +276.0% | 8 qtrs — |
| 19 | STATE STREET CORP | 62.1K +— (+0.0%) | 42.6K +11.6K (+37.5%) | 0.14% -0.001 pp | 0.00% +0.000 pp | USD7.52 -27.0% | 18 qtrs — |
| 20 | RANGELEY CAPITAL, LLC | 40.0K -43.0K (-51.8%) | 27.4K -14.0K (-33.7%) | 0.09% -0.096 pp | 0.02% -0.013 pp | USD0.50 +998.0% | 2 qtrs — |
| 21 | NORTHERN TRUST CORP | 38.1K +— (+0.0%) | 26.2K +7.1K (+37.5%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD7.16 -23.3% | 18 qtrs — |
| 22 | TWO SIGMA INVESTMENTS, LP | 37.0K +15.5K (+72.5%) | 25.4K +14.7K (+137.1%) | 0.08% +0.034 pp | 0.00% +0.000 pp | USD1.29 +325.6% | 7 qtrs — |
| 23 | PRUDENTIAL FINANCIAL INC | 29.1K -9.3K (-24.2%) | 20.0K +804.0 (+4.2%) | 0.06% -0.021 pp | 0.00% +0.000 pp | USD0.50 +998.0% | 2 qtrs — |
| 24 | VIRTU FINANCIAL LLC | 27.1K -12.2K (-31.0%) | 19.0K -1.0K (-5.0%) | 0.06% -0.027 pp | 0.00% 0.000 pp | USD0.34 +1,514.7% | 3 qtrs — |
| 25 | HRT FINANCIAL LP | 21.4K -10.8K (-33.6%) | 14.0K -2.0K (-12.5%) | 0.05% -0.024 pp | 0.00% +0.000 pp | USD0.35 +1,468.6% | 3 qtrs — |
| 26 | RESOURCES INVESTMENT ADVISORS, LLC. | 20.0K +— (+0.0%) | 13.7K +3.7K (+37.5%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD0.50 +998.0% | 2 qtrs — |
| 27 | TWO SIGMA ADVISERS, LP | 19.3K +19.3K (+100.0%) | 13.2K +13.2K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD5.49 +0.0% | 7 qtrs — |
| 28 | GSA CAPITAL PARTNERS LLP | 19.3K +19.3K (+100.0%) | 13.0K +13.0K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.001 pp | USD5.49 +0.0% | 1 qtrs NEW |
| 29 | GROUND SWELL CAPITAL, LLC | 15.4K +15.4K (+100.0%) | 10.6K +10.6K (+100.0%) | 0.03% +0.034 pp | 0.02% +0.022 pp | USD0.69 +0.0% | 1 qtrs NEW |
| 30 | GREAT VALLEY ADVISOR GROUP, INC. | 15.0K +— (+0.0%) | 10.3K +2.8K (+37.5%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD0.96 +471.9% | 5 qtrs — |
| 31 | UTAH RETIREMENT SYSTEMS | 13.2K +— (+0.0%) | 9.1K +2.5K (+37.5%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.57 -16.4% | 13 qtrs — |
| 32 | ACT ADVISORS, LLC. | 13.2K +13.2K (+100.0%) | 9.0K +9.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.004 pp | USD0.69 +0.0% | 1 qtrs NEW |
| 33 | MERCER GLOBAL ADVISORS INC /ADV | 10.0K +— (+0.0%) | 6.9K +1.9K (+37.5%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD0.96 +471.9% | 5 qtrs — |
| 34 | HARTFORD FINANCIAL MANAGEMENT INC. | 6.5K +— (+0.0%) | 4.5K +1.2K (+37.5%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.36 -49.3% | 7 qtrs — |
| 35 | BARCLAYS PLC | 5.7K -9.7K (-62.8%) | 3.9K -14.1K (-78.2%) | 0.01% -0.022 pp | 0.00% +0.000 pp | USD2.79 +96.8% | 16 qtrs — |
| 36 | MORGAN STANLEY | 4.6K +— (+0.0%) | 3.2K +868.0 (+37.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.97 +84.8% | 18 qtrs — |
| 37 | UBS GROUP AG | 4.6K +2.2K (+93.0%) | 3.1K +2.0K (+165.4%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD0.47 +1,068.1% | 14 qtrs — |
| 38 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.5K -5.7K (-55.6%) | 3.1K -2.0K (-38.9%) | 0.01% -0.013 pp | 0.00% 0.000 pp | USD1.22 +350.0% | 18 qtrs — |
| 39 | SBI SECURITIES CO., LTD. | 4.2K +— (+0.0%) | 2.9K +795.0 (+37.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.96 +471.9% | 5 qtrs — |
| 40 | CITIGROUP INC | 3.9K -6.0K (-60.3%) | 2.7K -2.2K (-45.4%) | 0.01% -0.013 pp | 0.00% +0.000 pp | USD0.50 +998.0% | 2 qtrs — |
| 41 | BNP PARIBAS ARBITRAGE, SNC | 980.00 +— (+0.0%) | 672.00 +183.0 (+37.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.96 +471.9% | 5 qtrs — |
| 42 | WELLS FARGO & COMPANY/MN | 300.00 +— (+0.0%) | 206.00 +56.0 (+37.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.08 +163.9% | 18 qtrs — |
| 43 | BANK OF AMERICA CORP /DE/ | 251.00 +35.0 (+16.2%) | 172.00 +65.0 (+60.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.08 +34.6% | 18 qtrs — |
| 44 | JPMORGAN CHASE & CO | 82.00 -800.0 (-90.7%) | 56.00 -384.0 (-87.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD7.12 -90.3% | 18 qtrs — |
| 45 | ALLWORTH FINANCIAL LP | 50.00 +— (+0.0%) | 35.00 +10.0 (+40.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.32 +115.6% | 3 qtrs — |
| 46 | JONES FINANCIAL COMPANIES LLLP | — -90.0 (-100.0%) | — -50.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 47 | CAPTRUST FINANCIAL ADVISORS | — -10.0K (-100.0%) | — -5.0K (-100.0%) | 0.00% -0.022 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 48 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | — -550.0 (-100.0%) | — -274.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 186.1K | 0.60% |
| 2 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 74.4K | 0.43% |
| 3 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 24.6K | 0.25% |
| 4 | Dimensional - US Small Cap ETF DFAS | 0.00% | 105.7K | 0.26% |
| 5 | Vanguard Extended Market ETF VXF | 0.00% | 458.6K | 0.05% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 836.66 | 0.17% |
| 7 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.1K | 0.03% |
| 8 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 11.3K | 0.17% |
| 9 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.94M | 0.03% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.2K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
155.9K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+155,905
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | ADAR1 Capital Management, LLC | 10% Owner | P-Purchase | A | Common Stock | 35,101 | 14.00 | 491.3K | 779,784 | I | ↗ |
| 2026-05-04 | ADAR1 Capital Management, LLC | 10% Owner | P-Purchase | A | Common Stock | 116,904 | 13.97 | 1.63M | 744,683 | I | ↗ |
| 2026-03-04 | FMR LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 211,798 | I | ↗ |
| 2026-02-23 | Lieber Jonathan I | Officer | S-Sale | D | Common Stock | 789 | 5.06 | 4.0K | 4,115 | D | ↗ |
| 2026-02-18 | MACKAY MARTIN | Director | A-Award | A | Option (Right to Buy) | 18,055 | 4.45 | 80.3K | 18,055 | D | ↗ |
| 2026-02-18 | Lieber Jonathan I | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 4,904 | D | ↗ |
| 2026-02-18 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 14,305 | 4.45 | 63.7K | 14,305 | D | ↗ |
| 2025-05-13 | Soteropoulos Paula | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | Nash Christine A | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | MACKAY MARTIN | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | Chung Wendy | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-05-13 | Boudreau Helen M | Director | A-Award | A | Option (Right to Buy) | 28,500 | 0.30 | 8.6K | 28,500 | D | ↗ |
| 2025-02-14 | Uden Stephen | Director / Officer | A-Award | A | Option (Right to Buy) | 453,700 | 0.76 | 344.8K | 453,700 | D | ↗ |
| 2025-02-14 | Ryder Steven | Officer | A-Award | A | Option (Right to Buy) | 180,000 | 0.76 | 136.8K | 180,000 | D | ↗ |
| 2025-02-14 | Lieber Jonathan I | Officer | A-Award | A | Option (Right to Buy) | 180,000 | 0.76 | 136.8K | 180,000 | D | ↗ |
| 2025-01-02 | MACKAY MARTIN | Director | A-Award | A | Option (Right to Buy) | 92,857 | 0.95 | 88.2K | 92,857 | D | ↗ |
| 2025-01-02 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 67,857 | 0.95 | 64.5K | 67,857 | D | ↗ |
| 2025-01-02 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 73,571 | 0.95 | 69.9K | 73,571 | D | ↗ |
| 2025-01-02 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 73,571 | 0.95 | 69.9K | 73,571 | D | ↗ |
| 2024-05-15 | Soteropoulos Paula | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | Nash Christine A | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | Chung Wendy | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-05-15 | Boudreau Helen M | Director | A-Award | A | Option (Right to Buy) | 16,500 | 1.91 | 31.5K | 16,500 | — | ↗ |
| 2024-02-15 | Uden Stephen | Director / Officer | A-Award | A | Option (Right to Buy) | 216,000 | 1.86 | 401.8K | 216,000 | — | ↗ |
| 2024-02-15 | Ryder Steven | Officer | A-Award | A | Option (Right to Buy) | 120,000 | 1.86 | 223.2K | 120,000 | — | ↗ |
| 2024-02-15 | MACKAY MARTIN | Director / Officer | A-Award | A | Option (Right to Buy) | 216,000 | 1.86 | 401.8K | 216,000 | — | ↗ |
| 2024-02-15 | Lieber Jonathan I | Officer | A-Award | A | Option (Right to Buy) | 120,000 | 1.86 | 223.2K | 120,000 | — | ↗ |
| 2024-01-02 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 27,118 | 2.40 | 65.1K | 27,118 | — | ↗ |
| 2024-01-02 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 29,096 | 2.40 | 69.8K | 29,096 | — | ↗ |
| 2023-05-17 | Soteropoulos Paula | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | Nash Christine A | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-05-17 | Chung Wendy | Director | A-Award | A | Option (Right to Buy) | 12,353 | 5.64 | 69.7K | 12,353 | — | ↗ |
| 2023-05-17 | Boudreau Helen M | Director | A-Award | A | Option (Right to Buy) | 15,490 | 5.64 | 87.4K | 15,490 | — | ↗ |
| 2023-03-14 | Lieber Jonathan I | — | P-Purchase | A | Common Stock | 5,000 | 5.21 | 26.1K | 5,000 | — | ↗ |
| 2023-03-07 | PARMAR KUSH | Director | S-Sale | D | Common Stock | 100,000 | 8.20 | 820.0K | 2,378,969 | — | ↗ |
| 2023-03-07 | 5AM Partners V, LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 8.20 | 820.0K | 2,378,969 | — | ↗ |
| 2023-02-06 | Uden Stephen | Officer | A-Award | A | Option (Right to Buy) | 214,000 | 6.50 | 1.39M | 214,000 | — | ↗ |
| 2023-02-06 | Ryder Steven | Officer | A-Award | A | Option (Right to Buy) | 119,000 | 6.50 | 773.5K | 119,000 | — | ↗ |
| 2023-02-06 | MACKAY MARTIN | Director / Officer | A-Award | A | Option (Right to Buy) | 214,000 | 6.50 | 1.39M | 214,000 | — | ↗ |
| 2023-02-01 | Lieber Jonathan I | Officer | A-Award | A | Option (Right to Buy) | 240,000 | 6.81 | 1.63M | 240,000 | — | ↗ |
| 2023-01-03 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 10,344 | 0.00 | — | 10,344 | — | ↗ |
| 2023-01-03 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 10,237 | 0.00 | — | 10,237 | — | ↗ |
| 2023-01-03 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 11,099 | 0.00 | — | 11,099 | — | ↗ |
| 2023-01-03 | Chung Wendy | Director | A-Award | A | Option (Right to Buy) | 9,482 | 0.00 | — | 9,482 | — | ↗ |
| 2022-11-15 | VIKING GLOBAL INVESTORS LP | Director | P-Purchase | A | Pre-Funded Warrants to Purchase Common Stock | 3,333,388 | 6.00 | 20.00M | 3,333,388 | — | ↗ |
| 2022-08-01 | Chung Wendy | Director | A-Award | A | Option (Right to Buy) | 26,880 | 0.00 | — | 26,880 | — | ↗ |
| 2022-06-03 | ROCKLAGE SCOTT M | Director | S-Sale | D | Common Stock | 99,671 | 12.50 | 1.25M | 2,478,969 | — | ↗ |
| 2022-06-03 | PARMAR KUSH | Director | S-Sale | D | Common Stock | 99,671 | 12.50 | 1.25M | 2,478,969 | — | ↗ |
| 2022-06-03 | 5AM Opportunities I, L.P. | 10% Owner | S-Sale | D | Common Stock | 99,671 | 12.50 | 1.25M | 2,478,969 | — | ↗ |
| 2022-05-24 | Soteropoulos Paula | Director | A-Award | A | Option (Right to Buy) | 13,440 | 12.75 | 171.4K | 13,440 | — | ↗ |
| 2022-05-24 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 13,440 | 0.00 | — | 13,440 | — | ↗ |
| 2022-05-24 | Nash Christine A | Director | A-Award | A | Option (Right to Buy) | 2,240 | 0.00 | — | 2,240 | — | ↗ |
| 2022-05-24 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 2,240 | 0.00 | — | 2,240 | — | ↗ |
| 2022-05-24 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 13,440 | 0.00 | — | 13,440 | — | ↗ |
| 2022-05-24 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 13,440 | 0.00 | — | 13,440 | — | ↗ |
| 2022-05-24 | Boudreau Helen M | Director | A-Award | A | Option (Right to Buy) | 13,440 | 0.00 | — | 13,440 | — | ↗ |
| 2022-05-23 | ROCKLAGE SCOTT M | Director | S-Sale | D | Common Stock | 33,553 | 13.00 | 436.2K | 1,302,084 | — | ↗ |
| 2022-05-23 | PARMAR KUSH | Director | S-Sale | D | Common Stock | 33,553 | 13.00 | 436.2K | 1,302,084 | — | ↗ |
| 2022-05-23 | 5AM Opportunities I, L.P. | 10% Owner | S-Sale | D | Common Stock | 66,447 | 13.00 | 863.8K | 2,578,640 | — | ↗ |
| 2022-04-04 | Nash Christine A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-04 | Liu Hui | Director | A-Award | A | Option (Right to Buy) | 26,880 | 0.00 | — | 26,880 | — | ↗ |
| 2022-03-21 | Fryer Jeffrey M | Officer | P-Purchase | A | Common Stock | 3,000 | 8.04 | 24.1K | 47,048 | — | ↗ |
| 2022-02-08 | PARMAR KUSH | Director | S-Sale | D | Common Stock | 139,539 | 13.05 | 1.82M | 2,645,087 | — | ↗ |
| 2022-02-08 | 5AM Opportunities I, L.P. | 10% Owner | S-Sale | D | Common Stock | 139,539 | 13.05 | 1.82M | 2,645,087 | — | ↗ |
| 2022-02-07 | Uden Stephen | Officer | A-Award | A | Option (Right to Buy) | 62,000 | 15.04 | 932.5K | 62,000 | — | ↗ |
| 2022-02-07 | Ryder Steven | Officer | A-Award | A | Option (Right to Buy) | 62,000 | 15.04 | 932.5K | 62,000 | — | ↗ |
| 2022-02-07 | MACKAY MARTIN | Director / Officer | A-Award | A | Option (Right to Buy) | 62,000 | 15.04 | 932.5K | 62,000 | — | ↗ |
| 2022-02-07 | Fryer Jeffrey M | Officer | A-Award | A | Option (Right to Buy) | 62,000 | 15.04 | 932.5K | 62,000 | — | ↗ |
| 2022-01-19 | Fryer Jeffrey M | Officer | P-Purchase | A | Common Stock | 1,400 | 8.70 | 12.2K | 44,048 | — | ↗ |
| 2022-01-13 | Uden Stephen | Officer | P-Purchase | A | Common Stock | 807 | 9.62 | 7.8K | 719,127 | — | ↗ |
| 2022-01-12 | Uden Stephen | Officer | P-Purchase | A | Common Stock | 5,000 | 10.55 | 52.8K | 714,127 | — | ↗ |
| 2022-01-11 | MACKAY MARTIN | Director / Officer | P-Purchase | A | Common Stock | 4,496 | 10.65 | 47.9K | 282,609 | — | ↗ |
| 2022-01-10 | MACKAY MARTIN | Director / Officer | P-Purchase | A | Common Stock | 5,504 | 10.10 | 55.6K | 278,113 | — | ↗ |
| 2022-01-07 | Fryer Jeffrey M | Officer | P-Purchase | A | Common Stock | 705 | 8.97 | 6.3K | 33,353 | — | ↗ |
| 2022-01-03 | Soteropoulos Paula | Director | A-Award | A | Option (Right to Buy) | 5,369 | 10.38 | 55.7K | 5,369 | — | ↗ |
| 2022-01-03 | SHANNON TIMOTHY M | Director | A-Award | A | Option (Right to Buy) | 6,041 | 10.38 | 62.7K | 6,041 | — | ↗ |
| 2022-01-03 | PARMAR KUSH | Director | A-Award | A | Option (Right to Buy) | 5,772 | 10.38 | 59.9K | 5,772 | — | ↗ |
| 2022-01-03 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 6,242 | 10.38 | 64.8K | 6,242 | — | ↗ |
| 2022-01-03 | HUNT RONALD | Director | A-Award | A | Option (Right to Buy) | 6,242 | 10.38 | 64.8K | 6,242 | — | ↗ |
| 2021-08-02 | SHANNON TIMOTHY M | Director | P-Purchase | A | Common Stock | 76,923 | 13.00 | 1,000.0K | 2,409,712 | — | ↗ |
| 2021-08-02 | PARMAR KUSH | Director | P-Purchase | A | Common Stock | 615,384 | 13.00 | 8.00M | 1,406,098 | — | ↗ |
| 2021-08-02 | Hopfner Robert Lorne | Director | P-Purchase | A | Common Stock | 576,923 | 13.00 | 7.50M | 2,267,411 | — | ↗ |
| 2021-08-02 | HUNT RONALD | Director | P-Purchase | A | Common Stock | 153,846 | 13.00 | 2.00M | 2,301,603 | — | ↗ |
| 2021-08-02 | FMR LLC | — | C-Conversion | A | Common Stock | 1,694,388 | 0.00 | — | 1,694,388 | — | ↗ |
| 2021-08-02 | 5AM Opportunities I, L.P. | 10% Owner | P-Purchase | A | Common Stock | 615,384 | 13.00 | 8.00M | 1,406,098 | — | ↗ |
| 2021-07-29 | VIKING GLOBAL INVESTORS LP | 10% Owner | C-Conversion | D | Series B Preferred Units | 21,578,387 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | Uden Stephen | Officer | — | D | Option (Right to Buy) | 160,000 | 13.00 | 2.08M | 0 | — | ↗ |
| 2021-07-29 | Soteropoulos Paula | Director | — | D | Common Stock | 0 | 0.00 | — | 23,882 | — | ↗ |
| 2021-07-29 | SHANNON TIMOTHY M | Director | — | D | Option (Right to Buy) | 13,440 | 13.00 | 174.7K | 0 | — | ↗ |
| 2021-07-29 | Ryder Steven | Officer | — | D | Option (Right to Buy) | 160,000 | 13.00 | 2.08M | 0 | — | ↗ |
| 2021-07-29 | PARMAR KUSH | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,784,626 | — | ↗ |
| 2021-07-29 | MACKAY MARTIN | Director / Officer | — | D | Option (Right to Buy) | 160,000 | 13.00 | 2.08M | 0 | — | ↗ |
| 2021-07-29 | Iancovici Lucian | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | Hopfner Robert Lorne | Director | — | D | Option (Right to Buy) | 13,440 | 13.00 | 174.7K | 0 | — | ↗ |
| 2021-07-29 | HUNT RONALD | Director | — | D | Option (Right to Buy) | 13,440 | 13.00 | 174.7K | 0 | — | ↗ |
| 2021-07-29 | Fryer Jeffrey M | Officer | — | D | Option (Right to Buy) | 160,000 | 13.00 | 2.08M | 0 | — | ↗ |
| 2021-07-29 | FMR LLC | 10% Owner | — | I | Series B Preferred Units | 1,694,388 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | Boudreau Helen M | Director | — | D | Option (Right to Buy) | 13,440 | 13.00 | 174.7K | 0 | — | ↗ |
| 2021-07-29 | 5AM Ventures V, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,778,216 | — | ↗ |
| 2021-07-28 | Uden Stephen | Officer | J-Other | D | Series A-2 Preferred Units | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-28 | SHANNON TIMOTHY M | Director | J-Other | A | Common Stock | 2,332,789 | 0.00 | — | 2,332,789 | — | ↗ |
| 2021-07-28 | PARMAR KUSH | Director | J-Other | D | Series B Preferred Units | 5,034,955 | 0.00 | — | 0 | — | ↗ |
| 2021-07-28 | MACKAY MARTIN | Director / Officer | J-Other | D | Series B Preferred Units | 107,891 | 0.00 | — | 0 | — | ↗ |
| 2021-07-28 | Hopfner Robert Lorne | Director | A-Award | A | Option (Right to Buy) | 13,440 | 13.00 | 174.7K | 13,440 | — | ↗ |
| 2021-07-28 | HUNT RONALD | Director | J-Other | D | Series B Preferred Units | 2,157,838 | 0.00 | — | 0 | — | ↗ |
| 2021-07-28 | Fryer Jeffrey M | Officer | J-Other | D | Series A-1 Preferred Units | 75,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-18.7K
Shares Outstanding
5.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Stephen Uden, M.D. Chief Executive Officer and President | 551.2K | — | — | 314.6K | 248.0K | 13.8K | 1.13M | 27.90% | ↗ |
| 2 | 2024 | Martin W. Mackay, Ph.D. Chairman, former Executive Chairman | 551.2K | — | — | 314.6K | 223.2K | 13.8K | 1.10M | 28.53% | ↗ |
| 3 | 2024 | Steven Ryder, M.D. Chief Medical Officer | 531.2K | — | — | 174.8K | 191.2K | 13.8K | 911.1K | 19.19% | ↗ |
| 4 | 2024 | Jonathan I. Lieber, M.B.A. Chief Financial Officer and Treasurer | 478.4K | — | — | 174.8K | 172.2K | 13.8K | 839.2K | 20.83% | ↗ |
| 5 | 2023 | Jonathan . Lieber, M.B.A. Chief Financial Officer and Treasurer | 422.7K | 100.0K | — | 1.25M | 118.1K | 26.4K | 1.91M | 65.11% | ↗ |
| 6 | 2023 | Jonathan I. Lieber, M.B.A. Chief Financial Officer and Treasurer | 422.7K | 100.0K | — | 1.25M | 118.1K | 13.2K | 1.90M | 65.56% | ↗ |
| 7 | 2023 | Martin W. Mackay, Ph.D. Executive Chairman and former Chief Executive Officer | 530.0K | — | — | 1.05M | 167.0K | 26.4K | 1.78M | 59.32% | ↗ |
| 8 | 2023 | Stephen Uden, M.D. Chief Executive Officer and President | 530.0K | — | — | 1.05M | 167.0K | 13.2K | 1.77M | 59.77% | ↗ |
| 9 | 2023 | Martin W. Mackay, Ph.D. Chairman, former Executive Chairman | 530.0K | — | — | 1.05M | 167.0K | 13.2K | 1.77M | 59.77% | ↗ |
| 10 | 2023 | Steven Ryder, M.D. Chief Medical Officer | 510.8K | — | — | 586.6K | 143.0K | 26.4K | 1.27M | 46.31% | ↗ |
| 11 | 2023 | Steven Ryder, M.D. Chief Medical Officer | 510.8K | — | — | 586.6K | 143.0K | 13.2K | 1.25M | 46.79% | ↗ |
| 12 | 2022 | Stephen Uden, M.D. Chief Executive Officer and President | 491.2K | — | — | 691.1K | 198.9K | 17.0K | 1.40M | 49.43% | ↗ |
| 13 | 2022 | Jeffrey M. Fryer, CPA Former Chief Financial Officer and Treasurer | 491.2K | — | — | 691.1K | 198.9K | 17.0K | 1.40M | 49.43% | ↗ |
| 14 | 2022 | Martin W. Mackay, Ph.D. Chief Executive Officer and Chairman | 491.2K | — | — | 691.1K | 198.9K | 17.0K | 1.40M | 49.43% | ↗ |
| 15 | 2022 | Stephen Uden, M.D. President, Chief Operating Officer and Chief Scientific Officer | 491.2K | — | — | 691.1K | 198.9K | 17.0K | 1.40M | 49.43% | ↗ |
| 16 | 2022 | Martin W. Mackay, Ph.D. Executive Chairman and former Chief Executive Officer | 491.2K | — | — | 691.1K | 198.9K | 17.0K | 1.40M | 49.43% | ↗ |
| 17 | 2021 | Martin W. Mackay, Ph.D. Chief Executive Officer and Chairman | 441.2K | — | 753.8K | 1.52M | 167.7K | 16.5K | 2.89M | 78.39% | ↗ |
| 18 | 2021 | Jeffrey M. Fryer, CPA Former Chief Financial Officer and Treasurer | 441.2K | — | 753.8K | 1.52M | 167.7K | 16.5K | 2.89M | 78.39% | ↗ |
| 19 | 2021 | Stephen Uden, M.D. President, Chief Operating Officer and Chief Scientific Officer | 441.2K | — | 753.8K | 1.52M | 167.7K | 16.5K | 2.89M | 78.39% | ↗ |
| 20 | 2021 | Jeffrey M. Fryer, CPA Chief Financial Officer and Treasurer | 441.2K | — | 753.8K | 1.52M | 167.7K | 16.5K | 2.89M | 78.39% | ↗ |
| 21 | 2020 | Stephen Uden, M.D. President, Chief Operating Officer and Chief Scientific Officer | 379.5K | — | 292.6K | — | 151.8K | 14.2K | 838.1K | 34.91% | ↗ |
| 22 | 2020 | Jeffrey M. Fryer, CPA Chief Financial Officer and Treasurer | 379.5K | — | 292.6K | — | 151.8K | 14.2K | 838.1K | 34.91% | ↗ |
| 23 | 2020 | Martin W. Mackay, Ph.D. Chief Executive Officer and Chairman | 379.5K | — | 292.6K | — | 151.8K | 14.2K | 838.1K | 34.91% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Uden | Co-Founder, President, Chief Executive Officer & Director | 858.0K | — |
| Steven W. Ryder | Chief Medical Officer | 747.1K | — |
| Jonathan I. Lieber | Chief Financial Officer & Treasurer | 645.5K | male |
| Martin W. MacKay | Co-Founder & Chairman | 290.0K | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RLYB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
